Over the course of the week, we made 1 new trades - 0 buys and 1 sells.
Click here for the Momentum Ranking of week 38.
This Week’s Trading Activity: Maintaining Momentum and Navigating Market Conditions
Welcome back to our weekly trading update! We’re committed to sharing insights and keeping you informed about our portfolio’s activity. This week, the S&P 500 continues to hover above its 200-day moving average, marking 219 consecutive days. This stability is a positive sign and means our strategy remains in full gear, aligning with Andreas Clenow’s momentum ranking approach detailed in his book, “Stocks On The Move”.
Buys and Sells
This week’s activity saw a few changes in our portfolio. We sold CRUS, a move triggered by our strategy’s rules. Curiously, there have been no new buys due to the lack of stocks meeting our strict criteria. Since the S&P 500 remains above its 200-day moving average, we remain vigilant for potential new opportunities, but have refrained from adding fresh positions in the meantime.
The most significant adjustment involved rebalancing—allocating more resources to strengthen existing positions. We increased our holdings in Texas Pacific Land Corporation (TPL) and United Therapeutics Corporation (UTHR), indicating our confidence in their continuing performance.
Summary
Currently, the majority of our portfolio remains in cash. This cautious stance allows us flexibility and readiness for market shifts. Our top holdings include cash, UTHR, and Corcept Therapeutics (CORT). It’s worth noting that LMB has been our best performer this week, with a gain of 18.55%, making it a standout amidst the market’s fluctuations. On the flip side, UTHR saw a minor dip of 0.19%, but we maintain confidence in its long-term potential.
Despite a quiet week in terms of new buys, our portfolio’s core remains robust. Our strategy continues to emphasize holding top-ranked stocks based on the annualized adjusted slope, rebalancing as necessary, and selling when stocks no longer qualify under our criteria. This discipline ensures that we’re always aligning with market momentum.
This week highlights the importance of sticking to a systematic approach, even when the market doesn’t offer new enticing buys. We’re focused on maintaining a solid foundation while being prepared to capitalize on new opportunities as they arise.
In conclusion, this week’s activity affirms the strength of our disciplined approach. We invite you to share your thoughts or questions in the comments below. Your feedback and engagement are always appreciated as we navigate the markets together. Thank you for following our journey, and we look forward to providing more updates next week!
This week’s transactions:
-
Sold:
-
Bought:
- No buys in this week!
-
Rebalanced / added:
-
Rebalanced / reduced:
- No positions were reduced in this week!
Index Distribution:
At the moment, we are holding mostly cash:
Current portfolio allocation:
The portfolio is in cash-mode right now, waiting for some good deals to come along:
Weekly sector distribution:
Current portfolio (@finviz):
| Symbol | Name | Index | Sector | MC | Dist to 52w High | pct |
|---|---|---|---|---|---|---|
| cash | Cash | Cash | Cash | – | 179828 | 0.92 |
| UTHR | United Therapeutics Corp | S&P 400 | Healthcare | 15.35B | -5.77% | 0.016 |
| CORT | Corcept Therapeutics Inc | Barrons 400 | Healthcare | 4.16B | 0.06% | 0.014 |
| HALO | Halozyme Therapeutics Inc. | S&P 400 | Healthcare | 7.81B | -5.97% | 0.013 |
| TPL | Texas Pacific Land Corporation | S&P 400 | Energy | 19.99B | -1.29% | 0.013 |
| LMB | Limbach Holdings Inc | Barrons 400 | Industrials | 828.68M | -3.52% | 0.011 |
| TBBK | Bancorp Inc. | Barrons 400 | Financial Services | 2.56B | -2.39% | 0.007 |
| LNTH | Lantheus Holdings Inc | S&P 400 | Healthcare | 7.36B | -16.47% | 0.006 |
As always, more trades next week!